Protocol Page


	Study ID (Protocol Number)
	CA209-016


	STUDY LOCATIONS*
	Beth Israel Deaconess Medical Center Boston, MA 02215 Recruiting	Cleveland Clinic Cleveland, OH 44195 Recruiting
	City Of Hope Duarte, CA 91010-3000 Recruiting	Dartmouth-Hitchcock Medical Center Lebanon, NH 03756 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)
	STUDY OVERVIEW
	The purpose is to determine the safety, effectiveness and best dose to use when giving Nivolumab in combination with Sunitinib, Pazopanib, or Ipilimumab for the treatment of metastatic renal cell carcinoma

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.